Indian tribunal asks Daiichi Sankyo to up Zenotech offer price
This article was originally published in Scrip
India's Securities Appellate Tribunal (SAT) has directed Daiichi Sankyo to revise its offer price for acquiring an additional 20% stake in the Indian biotech company, Zenotech Laboratories, to Rs160 per share from Rs113.62.
You may also be interested in...
New rules in India specify that a marketer of a drug will share the onus for quality and compliance along with the manufacturer. Enhanced punishment for misleading advertisements for a range of illnesses is also proposed, while calls for a statute to regulate pharma's marketing practices grow louder.
Former managing director of Janssen India to helm Bharat Serums and Vaccines following the firm’s acquisition by private equity firm Advent International.
Deal news from Strides Pharma, Pharmaceutics Intl., Cipla, Wanbury, AstraZeneca, Syntekabio, Arctoris, Mundipharma, Samsung Bioepis…